

PRESS RELEASE
16 June 2022 08:30:00 CEST

A3P Biomedical initiates partnership with Unilabs for Stockholm3

A3P Biomedical and Unilabs have initiated a partnership for Stockholm3, A3P Biomedical's blood test for early detection of aggressive prostate cancer. Screening by Stockholm3 is requested by healthcare providers throughout Sweden. The fact that Unilabs now includes Stockholm3 in its catalogue of products will make it possible for more patients to take the test, and at the same time improve logistics for the healthcare providers.

"Stockholm3 has the potential to radically improve prostate cancer diagnostics and we would like to provide this opportunity to both patients and caregivers. The test is integrated into the patient's regular medical record and sampling can either be done at our or the care provider's own lab and follow the regular route. This means that we can offer a very attractive and flexible solution", says Thomas Lindahl, Medical Director of Unilabs Sweden.

"We are very pleased with the Unilabs partnership. It will give men and care providers access to Stockholm3, not just in the Stockholm and Värmland regions, which is the case today. This will contribute to a faster rollout of Stockholm3 and more efficient cancer diagnostics throughout the country", says David Rosén, CEO of A3P Biomedical.

The agreement means that care providers can order Stockholm3 through Unilab's regular catalogue in the lab portal "Labportalen" (InfoSolutions). The patient is offered sampling at one of Unilabs' laboratories in Sweden, or at the care provider's facilities. The sample follows the same distribution route as the other tests Unilabs offers. The Stockholm3 analysis is performed by A3P Biomedical, and the result is delivered electronically via Unilabs to the care provider.

Prostate cancer is the most common form of cancer in Sweden with approximately 2,400 deaths each year.

Stockholm3 is a blood test that radically improves early detection of aggressive prostate cancer and reduces the number of unnecessary prostate biopsies, compared to PSA which is the traditional blood test for detecting prostate cancer. Stockholm3 has very strong clinical evidence based on studies including more than 75,000 men and has been in clinical use in Sweden and Norway since 2017.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[A3P Biomedical initiates partnership with Unilabs for Stockholm3](#)